Comments on: No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia http://www.audiomedica.com/global-health-issues/no-use-of-hydroxyurea-in-country-with-most-sickle-cell-anemia/ Mon, 02 Jan 2012 16:08:21 +0000 hourly 1 By: Lisa Ahramjian http://www.audiomedica.com/global-health-issues/no-use-of-hydroxyurea-in-country-with-most-sickle-cell-anemia/comment-page-1/#comment-1989 Lisa Ahramjian Tue, 08 Jan 2008 21:03:37 +0000 http://www.audiomedica.com/global-health-issues/no-use-of-hydroxyurea-in-country-with-most-sickle-cell-anemia/#comment-1989 NIH Consensus Development Conference: Hydroxyurea Treatment for Sickle Cell Disease February 25–27, 2008 Register Online Now! In order to take a closer look at this important topic, the National Heart, Lung, and Blood Institute and the Office of Medical Applications of Research of the National Institutes of Health will convene a Consensus Development Conference from February 25–27, 2008, to assess the available scientific evidence related to the following questions: What is the efficacy (results from clinical studies) of hydroxyurea treatment for patients who have sickle cell disease in three groups: infants, preadolescents, and adolescents/adults? What is the effectiveness (in everyday practice) of hydroxyurea treatment for patients who have sickle cell disease? What are the short- and long-term harms of hydroxyurea treatment? What are the barriers to hydroxyurea treatment for patients who have sickle cell disease and what are the potential solutions? What are the future research needs? Additional information is available at http://consensus.nih.gov/2008/2008SickleCellCDC119main.htm NIH Consensus Development Conference:
Hydroxyurea Treatment for Sickle Cell Disease
February 25–27, 2008

Register Online Now!

In order to take a closer look at this important topic, the National Heart, Lung, and Blood Institute and the Office of Medical Applications of Research of the National Institutes of Health will convene a Consensus Development Conference from February 25–27, 2008, to assess the available scientific evidence related to the following questions:

What is the efficacy (results from clinical studies) of hydroxyurea treatment for patients who have sickle cell disease in three groups: infants, preadolescents, and adolescents/adults?

What is the effectiveness (in everyday practice) of hydroxyurea treatment for patients who have sickle cell disease?

What are the short- and long-term harms of hydroxyurea treatment?

What are the barriers to hydroxyurea treatment for patients who have sickle cell disease and what are the potential solutions?

What are the future research needs?

Additional information is available at http://consensus.nih.gov/2008/2008SickleCellCDC119main.htm

]]>